ClinicalTrials.gg
TerminatedNCT02742519Updated Nov 19, 2018Results posted

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

A Phase 3 interventional study of ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 6 sites in 3 countries. Open to participants aged 3 Years to 5 Years. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Why this study was terminated
Low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
3 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
76th of 84
14 · median 70
Started
2016
with 9 others
Phase 3
45 of 84
none open now
Registered
40th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 76th largest by enrollment, is one of 10 that started in 2016, is one of 45 in phase 3, and was the 40th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 3 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI), in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance regulator (CFTR) gating mutation

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
3 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF.
  • Must have 1 of the following CFTR gating mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D.
  • Hematology, serum chemistry, and coagulation at Screening with no abnormalities or concomitant diagnosis that would interfere with the LCI and CT scan study assessments, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1
  • Any laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject (in the opinion of the investigator)
  • Abnormal liver function, at Screening, defined as ≥3 × (ULN), of any 3 or more of the following: serum (AST), serum alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum alkaline phosphatase (ALP), and total
  • History of solid organ or hematological transplantation
  • Any clinically significant "non-CF-related" illness within 2 weeks before Day 1
  • Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1
  • Participation in a clinical study involving administration of either an or a marketed drug within 30 days or 5 terminal half-lives (whichever is longer or as determined by the local requirements) before Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Part 1-Sequence 1

    ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2

    Drug: ivacaftor · Drug: Placebo

  • Experimental
    Part 1 - Sequence 2

    placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2

    Drug: ivacaftor · Drug: Placebo

  • Experimental
    Part 2: ivacaftor

    open label period

    Drug: ivacaftor

Interventions

  • Also known as: VX-770

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5)

    LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

    Time frame: Baseline Through Week 8 for each treatment period, Up to 24 Weeks

Secondary outcomes

  1. Absolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8

    Serum samples were collected for evaluation of change in immunoreactive trypsinogen levels at Week 8.

    Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks

  2. Absolute Change From Baseline in Fecal Elastase-1 Levels at Week 8

    Fecal elastase-1 was used clinically to diagnose pancreatic exocrine insufficiency in participants with cystic fibrosis.

    Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks

  3. Absolute Change From Baseline in Weight at Week 8

    Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks

  4. Absolute Change From Baseline in Body Mass Index (BMI) at Week 8

    BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

    Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks

  5. Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Month 15

07

Results

Posted Nov 19, 2018
Limitations and caveats
Vertex terminated the study early because of enrollment futility.

Participant flow

Part 1 Treatment Period 1 (8 Weeks)
Participant flow — Part 1 Treatment Period 1 (8 Weeks)
MilestonePart 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started860
Completed860
Not completed000
Part 1 Treatment Period 2 (8 Weeks)
Participant flow — Part 1 Treatment Period 2 (8 Weeks)
MilestonePart 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started860
Completed750
Not completed110
Withdrew: Availability of commercial drug110
Part 2 Open Label Period (32 Weeks)
Participant flow — Part 2 Open Label Period (32 Weeks)
MilestonePart 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started0010
Completed000
Not completed0010
Withdrew: Availability of commercial drug009
Withdrew: Other001

Outcome measures

PrimaryAbsolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5)

LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.

Time frame:
Baseline Through Week 8 for each treatment period, Up to 24 Weeks
Reported as:
Mean · Lung clearance index
Absolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5)
Lung clearance indexPlacebo (Crossover Part)Ivacaftor (Crossover Part)
Absolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5)-0.07 ± 0.93-0.53 ± 1.23
Statistical analysis
  • Placebo (Crossover Part) vs Ivacaftor (Crossover Part) · t-test, 2 sided · p = 0.2121
SecondaryAbsolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8

Serum samples were collected for evaluation of change in immunoreactive trypsinogen levels at Week 8.

Time frame:
Baseline and Week 8 of each treatment period, Up to 24 Weeks
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Absolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8
Nanogram per milliliter (ng/mL)Placebo (Crossover Part)Ivacaftor (Crossover Part)
Absolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8-9.3 ± 18.4-15.5 ± 6.5
SecondaryAbsolute Change From Baseline in Fecal Elastase-1 Levels at Week 8

Fecal elastase-1 was used clinically to diagnose pancreatic exocrine insufficiency in participants with cystic fibrosis.

Time frame:
Baseline and Week 8 of each treatment period, Up to 24 Weeks
Reported as:
Mean · microgram per gram (mcg/g)
Absolute Change From Baseline in Fecal Elastase-1 Levels at Week 8
microgram per gram (mcg/g)Placebo (Crossover Part)Ivacaftor (Crossover Part)
Absolute Change From Baseline in Fecal Elastase-1 Levels at Week 8-17.0 ± 55.423.1 ± 37.9
SecondaryAbsolute Change From Baseline in Weight at Week 8
Time frame:
Baseline and Week 8 of each treatment period, Up to 24 Weeks
Reported as:
Mean · Kilogram (kg)
Absolute Change From Baseline in Weight at Week 8
Kilogram (kg)Placebo (Crossover Part)Ivacaftor (Crossover Part)
Absolute Change From Baseline in Weight at Week 80.9 ± 1.01.1 ± 0.9
SecondaryAbsolute Change From Baseline in Body Mass Index (BMI) at Week 8

BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).

Time frame:
Baseline and Week 8 of each treatment period, Up to 24 Weeks
Reported as:
Mean · Kilogram per meter square (kg/m^2)
Absolute Change From Baseline in Body Mass Index (BMI) at Week 8
Kilogram per meter square (kg/m^2)Placebo (Crossover Part)Ivacaftor (Crossover Part)
Absolute Change From Baseline in Body Mass Index (BMI) at Week 80.13 ± 0.790.32 ± 0.59
SecondaryNumber of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to Month 15
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlacebo (Crossover Part)Ivacaftor (Crossover Part)Ivacaftor (Open Label Part)
Participants with any AEs11116
Participants with SAEs000

Adverse events

Collected over Baseline up to Month 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Crossover Part)0/13 (0%)0/13 (0%)11/13 (84.6%)
Ivacaftor (Crossover Part)0/13 (0%)0/13 (0%)11/13 (84.6%)
Ivacaftor (Open Label Part)0/10 (0%)0/10 (0%)6/10 (60%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo (Crossover Part)Ivacaftor (Crossover Part)Ivacaftor (Open Label Part)
CoughSkin and subcutaneous tissue disorders3/132/134/10
VomitingGastrointestinal disorders1/133/133/10
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/133/133/10
Productive coughRespiratory, thoracic and mediastinal disorders3/133/130/10
HeadacheNervous system disorders3/131/130/10
Upper respiratory tract infectionInfections and infestations1/133/131/10
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/132/130/10
Haemophilus test positiveInvestigations0/131/131/10
Streptococcus test positiveInvestigations0/130/131/10
WheezingRespiratory, thoracic and mediastinal disorders0/130/131/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorTotal
Mean3.6 ± 0.74.2 ± 1.03.9 ± 0.9
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorTotal
Female415
Male459
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 Sequence 1: Ivacaftor First, Then PlaceboPart 1 Sequence 2: Placebo First, Then IvacaftorTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8614
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Parkville, Victoria, Australia
  • South Brisbane, Australia
  • Subiaco, Australia
  • Westmead, Australia
  • Toronto, Ontario, Canada
  • London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2016
First posted
Apr 19, 2016
Start
May 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Nov 19, 2018
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02742519
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
May 2016
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Nov 19, 2018
Last update
Nov 19, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion